[go: up one dir, main page]

MX2015005448A - Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2). - Google Patents

Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).

Info

Publication number
MX2015005448A
MX2015005448A MX2015005448A MX2015005448A MX2015005448A MX 2015005448 A MX2015005448 A MX 2015005448A MX 2015005448 A MX2015005448 A MX 2015005448A MX 2015005448 A MX2015005448 A MX 2015005448A MX 2015005448 A MX2015005448 A MX 2015005448A
Authority
MX
Mexico
Prior art keywords
loxl2
therapeutic
lysyl oxidase
diagnostic methods
methods related
Prior art date
Application number
MX2015005448A
Other languages
English (en)
Inventor
Victoria Smith
Joanne I Adamkewicz
Susan K Lyman
Jason Chien
Xiaoming Li
Lixin Shao
Jeffrey D Bornstein
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MX2015005448A publication Critical patent/MX2015005448A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90605—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4)
    • G01N2333/90633—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general
    • G01N2333/90638—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3) in general with a definite EC number (1.4.3.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan métodos terapéuticos, de diagnóstico y pronóstico de la enfermedad, incluyendo enfermedades asociadas con fibrosis y cáncer utilizando agentes que se unen a, inhiben y/o detectan lisil oxidasa-tipo 2 (LOXL2) y agentes, composiciones, kits, sistemas de ensayo y dispositivos para utilizar con dichos métodos.
MX2015005448A 2012-10-30 2013-10-30 Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2). MX2015005448A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720350P 2012-10-30 2012-10-30
US201261724858P 2012-11-09 2012-11-09
PCT/US2013/067591 WO2014070939A1 (en) 2012-10-30 2013-10-30 Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)

Publications (1)

Publication Number Publication Date
MX2015005448A true MX2015005448A (es) 2015-11-06

Family

ID=49585588

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005448A MX2015005448A (es) 2012-10-30 2013-10-30 Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).

Country Status (12)

Country Link
US (2) US20140120102A1 (es)
EP (2) EP2914632A1 (es)
JP (2) JP2016500700A (es)
KR (1) KR20150074179A (es)
CN (2) CN104755501A (es)
AU (2) AU2013337908A1 (es)
CA (1) CA2889208A1 (es)
EA (1) EA201590630A1 (es)
HK (2) HK1214615A1 (es)
MX (1) MX2015005448A (es)
SG (2) SG10201703240RA (es)
WO (1) WO2014070939A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2537529B1 (en) 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2 inhibitory antibodies and uses thereof
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
US20150342943A1 (en) * 2014-06-03 2015-12-03 Gilead Sciences, Inc. Methods of treating liver disease
CA2951535A1 (en) * 2014-06-11 2015-12-17 Gilead Sciences, Inc. Methods for treating cardiovascular diseases
EP3193855B1 (en) 2014-09-17 2021-05-19 Recurium IP Holdings, LLC Bicyclic compounds
WO2016049070A1 (en) * 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methods of treating liver disease
US20190022116A1 (en) 2014-12-26 2019-01-24 Emory University N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
SG11201707246YA (en) 2015-03-06 2017-10-30 Pharmakea Inc Fluorinated lysyl oxidase-like 2 inhibitors and uses thereof
GB201602934D0 (en) 2016-02-19 2016-04-06 Cancer Res Inst Royal Compounds
BR112019004517A2 (pt) * 2016-09-07 2019-08-13 Pharmakea, Inc. formas cristalinas de um inibidor lisil-oxidase-semelhante 2 e métodos de preparação
AU2017324930A1 (en) * 2016-09-07 2019-04-11 Pharmakea, Inc. Chemical probes of lysyl oxidase-like 2 and uses thereof
KR102615565B1 (ko) * 2016-09-07 2023-12-18 파마케아, 인크. 리실 옥시다제 유사 2 억제제의 용도
GB201704206D0 (en) * 2017-03-16 2017-05-03 Nordic Bioscience As Lysyl oxidase like-2 assay
DK3706762T3 (da) 2017-12-07 2024-12-16 Univ Emory N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN111118142A (zh) * 2020-01-17 2020-05-08 上海市同济医院 血清赖氨酸氧化酶作为肾间质纤维化的分层诊断性生物标志物
WO2021155439A1 (en) * 2020-02-05 2021-08-12 Pharmaxis Ltd. Bioprobes for lysyl oxidases and uses thereof
CN116064765B (zh) * 2022-08-02 2023-09-05 首都医科大学附属北京友谊医院 检测loxl1基因突变的物质在制备肝纤维化患者分子分型的产品中的应用
CN120518770B (zh) * 2025-05-21 2025-12-09 北京大学人民医院 一种抗loxl2纳米抗体或抗原结合片段与应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
EP2537529B1 (en) * 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2 inhibitory antibodies and uses thereof
KR20120054077A (ko) * 2009-08-21 2012-05-29 길리아드 바이오로직스, 인크. 폐 섬유증 장애의 치료를 위한 방법 및 조성물
CA2771630A1 (en) * 2009-08-21 2011-02-24 Victoria Smith Therapeutic methods and compositions
US20110044907A1 (en) * 2009-08-21 2011-02-24 Derek Marshall In vivo screening assays
CA2789022A1 (en) 2010-02-04 2011-08-11 Gilead Biologics, Inc. Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
US10092552B2 (en) * 2011-01-31 2018-10-09 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
PE20141450A1 (es) * 2011-06-01 2014-11-06 Gilead Biologics Inc Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo

Also Published As

Publication number Publication date
AU2016256820A1 (en) 2016-12-01
CN107982531A (zh) 2018-05-04
EP3348576A1 (en) 2018-07-18
JP2018083845A (ja) 2018-05-31
SG10201703240RA (en) 2017-06-29
JP2016500700A (ja) 2016-01-14
HK1214615A1 (zh) 2016-07-29
HK1212356A1 (en) 2016-06-10
CN104755501A (zh) 2015-07-01
EP2914632A1 (en) 2015-09-09
AU2013337908A1 (en) 2015-04-30
EA201590630A1 (ru) 2015-10-30
SG11201503065PA (en) 2015-05-28
WO2014070939A1 (en) 2014-05-08
US20140120102A1 (en) 2014-05-01
KR20150074179A (ko) 2015-07-01
US20170327595A1 (en) 2017-11-16
CA2889208A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
MX2015005448A (es) Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
MA34058B1 (fr) Formes de rifaximine, et leurs utilisations
WO2014026768A8 (en) Colorectal cancer markers
WO2008089397A3 (en) Adrb2 cancer markers
CA2865011C (en) Methods and compositions for treating huntington's disease
CR20120202A (es) Métodos y composiciones para tratar cáncer
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
EA201391351A1 (ru) Способы повышения эффективности folr1 терапии рака
GB2522366A (en) Mapping cytosine modifications
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
ECSP14014544A (es) Compuestos terapéuticamente activos y sus métodos de uso
HK1202313A1 (en) Methods and compositions for the treatment and diagnosis of bladder cancer
WO2012158780A3 (en) Lung cancer signature
MD20130098A2 (ro) Test pentru determinarea lizil oxidazei-2 şi metode de utilizare a acestuia
WO2012143481A3 (en) Prostate cancer markers
MX349802B (es) Uso de aril- y hetarilcarboxamidas como endoparasiticidas.
WO2013106747A3 (en) Methods and compositions for the treatment and diagnosis of thyroid cancer
CL2013001324A1 (es) Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
EA201890598A3 (ru) Антиандрогены для лечения неметастатического кастрационно-резистентного рака простаты
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
TWD160320S (zh) 便條施配器
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
BR112017016880A2 (pt) métodos de avaliação genômica em gado
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same